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Aims Transcatheter treatment of heart valve disease is well established today. However, for the treatment of tricuspid
regurgitation (TR), no effective catheter-based approach is available. Herein, we report the ﬁrst human case
description of transcatheter treatment of severe TR in a 79-year-old patient with venous congestion and associated
non-cardiac diseases. In this patient, surgical treatment had been declined and pharmacological therapy had been
ineffective. After ex vivo and animal studies, the treatment of TR was performed by percutaneous caval valve
implantation.
Methods
and results
In a transcatheter approach through the right femoral vein, a custom-made self-expanding heart valve was implanted
into the inferior vena cava (IVC). The device was anchored in the IVC at the cavoatrial junction with the level of the
valve aligned immediately above the hepatic inﬂow and protruding into the right atrium. After deployment, excellent
valve function was observed resulting in a marked reduction in caval pressure and an abolition of the ventricular wave
in the IVC. Sequential echocardiographic exams over a follow-up period of 8 weeks conﬁrmed continuous device
function without paravalvular leakage or remaining venous regurgitation. The patient experienced improved physical
capacity and was able to resume off-bed activities. There was no recurrence of right heart failure during follow-up and
a partial reduction of ascites. The patient was discharged from hospital into a rehabilitation programme.
Conclusion Transcatheter treatment of severe TR by caval valve implantation is feasible resulting in an immediate abolition of IVC
regurgitation and mid-term clinical improvement. Thus, in selected non-surgical patients, caval valve implantation may
become a therapeutic option to treat venous regurgitation and improve associated non-cardiac diseases. Further con-
ﬁrmatory experience with longer follow-up is required to evaluate the long-term clinical beneﬁt of the procedure as
well as potential deleterious effects.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Since the ﬁrst human percutaneous valve replacement by Bon-
hoeffer et al.
1 10 years ago, interventional treatment of heart
valve disease has rapidly advanced. Today, transcatheter
therapy has gained increasing acceptance as a treatment
option for patients with aortic-, mitral- and pulmonic valve
disease, who are at high risk for conventional surgery.
2–4
Despite these advances, no catheter-based approach is yet avail-
able for the treatment of tricuspid regurgitation (TR) and only
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5–7 Surgical
tricuspid valve (TV) repair is the only available treatment option
and most repairs are performed in the context of other planned
cardiac surgery. As severe TR is often associated with late-stage
myocardial or left heart valve disease, reoperations for recurrent
TR are particularly high-risk procedures.
8–10 A readily available
transcatheter approach could offer a treatment alternative, par-
ticularly for patients currently considered inoperable.
From the interventional perspective, there are two principle
concepts regarding the possible site of percutaneous valve
implantation—orthotopic vs. heterotopic TV replacement. For
orthotopic valve replacement, the prosthetic valve is positioned
in the TV annulus which, however, offers little resistance for
long-term valve ﬁxation due to its anatomic structure and ﬂex-
ible nature. Thus, orthotopic TV replacement would require
innovative solutions for stent and valve ﬁxation and has not
yet been reported in human patients. Heterotopic TV implan-
tation is an alternative approach involving valve implantation in
the central venous position at the cavoatrial junction. This
novel concept recently suggested by our group has been exten-
sively investigated in pre-clinical studies which demonstrated the
haemodynamic effect of caval valves in animals for up to 6
months of follow-up.
11 Thus, heterotopic valve implantation
offers a potential therapeutic option for inoperable patients suf-
fering from severe TR with venous congestion. Herein, we
report the ﬁrst-in-man application of this treatment concept
for severe TR involving inferior caval valve implantation.
Methods
Patient
The procedure was performed as ‘compassionate treatment’ in a
79-year-old female patient with severe functional TR. Upon evaluation
by a multidisciplinary team (cardiologist, cardiac surgeon), the patient
was considered inoperable due to multiple previous open-heart sur-
geries, signiﬁcant co-morbidities (including chronic kidney dysfunction,
logistic EuroScore 29.7%), as well as for technical reasons. Her medical
history included open surgical valvuloplasty for rheumatic mitral valve
stenosis in 1966, mitral valve replacement with a mechanical tilt-disc
prosthesis in 1986, and TV repair by a partial purse-string suture tech-
nique (‘DeVega-technique’) in 2000. Transthoracic echocardiography
had revealed recurrent functional TR grade IV with right ventricular
(RV) enlargement and mildly reduced RV function [tricuspid annular
plane systolic excursion (TAPSE) 16 mm; tricuspid annular systolic vel-
ocity (TASV) 6.3 cm/s). Left ventricular function was preserved (ejec-
tion fraction 65%). Right heart catheterization and angiography
conﬁrmed severe TR with massive venous regurgitation. The mean
pulmonary artery pressure was lightly elevated at 29 mmHg with a
normal pulmonary vascular resistance at 123 dyn s/cm
5. Haemo-
dynamic evaluation conﬁrmed a prominent ventricular wave of
30 mmHg in the right atrium (RA) and in the inferior vena cava
(IVC) which was transmitted down to the femoral veins (Figure 1A).
A computed tomographic (CT) angiogram performed for diagnostic
purpose visualized massive venous backﬂow of contrast from the RA
into the IVC down to the renal veins (Figure 1B).
Throughout the past years, the patient had suffered from progress-
ive symptoms of RV congestion with peripheral oedema, cirrhose
Figure 1 Severe tricuspid regurgitation with inferior vena cava congestion before device implantation. (A) Right heart catheterization con-
ﬁrms a prominent ventricular wave of 30 mmHg in the right atrium and the inferior vena cava which is transmitted down to the femoral
veins. (B) A computed tomographic angiogram with contrast injected into the superior vena cava visualized massive backﬂow into the IVC
down to the level of the renal veins. RA, right atrium; IVC, inferior vena cava; HV, hepatic vein; LA, left atrium; PA, pulmonary artery.
A. Lauten et al. 1208cardiaque, and persistent ascites with gastrointestinal dysfunction.
Recent deterioration of symptoms refractory to pharmacological treat-
ment made it impossible to resume off-bed activities. Under these cir-
cumstances, institutional review board approval was obtained and the
patient consented to attempt transcatheter caval valve implantation.
Device
A self-expanding percutaneous heart valve was designed for implan-
tation into the IVC to protect the abdominal vasculature from elevated
venous pressure and systolic backﬂow in severe TR. To avoid occlu-
sion of hepatic vein inﬂow just below the diaphragm, the device was
designed with the upper valve segment protruding into the RA and
the lower segment for anchoring in the IVC. Prior to manufacturing
the device, a CT angiogram was obtained to assess the anatomy and
diameter of the uppermost IVC segment and the cavoatrial junction.
A self-expanding tubular stent was then tailored to the dimension of
the anticipated landing zone in the IVC and manufactured of nitinol
by laser-cutting. The stent frame was shaped like an hourglass with a
total length of 70 mm, a maximum diameter of 43 mm, and the
middle segment constrained to facilitate ﬁxation at the cavoatrial junc-
tion. The proximal stent segment was then mounted with a tri-leaﬂet
porcine pericardial valve and a sleeve covering the inside down to the
base of the leaﬂets to prevent paravalvular leakage (Figure 2A). Valve
function and anchoring force were tested using a prototype device
in an ex vivo pulse duplicator model which demonstrated satisfactory
short-term function under simulated venous low-ﬂow conditions.
The device was stored in 0.2% glutaraldehyde until use.
Procedure
The implantation procedure was performed under general anaesthesia
and mechanical ventilation in a hybrid operating room. A 5 F arterial
catheter was placed in the left femoral artery and used for continuous
blood pressure monitoring. Two 7 F sheaths were placed in the right
internal jugular vein and the left femoral vein for pressure measure-
ment. Prior to valve implantation, conﬁrmatory right heart
catheterization was performed. An angiogram of the IVC and the RA
was obtained conﬁrming severe TR with regurgitation of contrast
into the caval and hepatic veins. Two 7 F pigtail catheters were then
positioned in the RA and IVC for continuous pressure monitoring.
Prior to implantation, the prosthetic valve was rinsed in saline, care-
fully crimped in iced water, and loaded into a custom-made 27 F
implantation catheter (Figure 2B). After puncture of the right femoral
vein, a straight 0.035 in. guidewire was placed in the vein. After a
small skin incision, the catheter was easily advanced in the Seldinger
technique through the femoral vein and the IVC into the RA. After
conﬁrming the catheter position under ﬂuoroscopic and echocardio-
graphic visualization, the uppermost 20 mm of the valve was partially
unloaded. The constrained segment of the stent frame was then
aligned with the cavoatrial junction by careful pullback of the catheter.
With a safety margin of  5 mm, care was taken to avoid a low or high
valve position causing either hepatic vein obstruction or paravalvular
regurgitation. After a satisfactory position was conﬁrmed, the device
was released from the catheter.
Transoesophageal echocardiography was performed immediately
after the procedure and repeated every 2 weeks after implantation.
Transthoracic echocardiography and abdominal sonography were
obtained 24 h and 7 days after the implantation. A CT angiogram
was performed after 8 weeks of follow-up.
Results
Haemodynamic measurements
Immediately after deployment, excellent function of the device was
observed. Transoesophageal echo conﬁrmed valvular competence
with full systolic closure and diastolic opening of the leaﬂets
without any sign of paravalvular regurgitation (Figure 3). Haemo-
dynamic measurements conﬁrmed a nearly abolished ventricular
wave in the IVC from 29/19 to 19/12 mmHg and mean IVC
Figure 2 Self-expanding percutaneous heart valve for inferior vena cava implantation. (A) The device was designed with the upper valve
segment protruding into the right atrium and the lower segment for anchoring in the inferior vena cava. The middle segment constrained
to facilitate ﬁxation at the cavoatrial junction. The proximal stent segment is mounted with a tri-leaﬂet porcine pericardial valve and a
sleeve covering the inside down to the base of the leaﬂets. (B) The valve was loaded into a 27 F catheter for implantation.
Heterotopic transcatheter TV implantation 1209pressure decreased from 19 to 16 mmHg (Figure 4A). Right atrial
pressure increased from 28/10 to 38/13 mmHg after valve implan-
tation (Table 1). The patient remained haemodynamically stable at
all times during the implantation and was extubated within 30 min
after the procedure. After an uneventful early post-operative
course, she was transferred from the intensive care unit to the
ward on the following day.
Assessment of valve function during
follow-up
Valve function remained excellent during the ﬁrst 8 weeks of
follow-up. Doppler interrogation of the valve conﬁrmed valvular
competence and a continuously antegrade blood ﬂow in the IVC
and the hepatic veins without ﬂow reversal. By planimetry, the
prosthetic valve area was 2.9 cm
2 with a mean transvalvular gradi-
ent ,1 mmHg. After 8 weeks, a CT angiogram demonstrated valv-
ular competence without regurgitation of contrast into the IVC
(Figure 4B). An unchanged forward-tilting position of the prosthetic
valve was conﬁrmed in a supine position related to the anatomic
course of the IVC (Figure 4C).
Clinical evolution
After device implantation, diuretic therapy was left unchanged.
Within the ﬁrst 8 weeks after implantation, the patient experi-
enced a gradual improvement of symptoms related to venous con-
gestion and right heart failure. Femoral venous pulsation was no
longer detectable after implantation and the patient was able to
resume off-bed activities and walk on the ward without assistance
after 4 days. Early after the procedure, the patient suffered from
temporary neck pain and recurring epistaxis, which subsided
when anticoagulation with heparin was discontinued and replaced
by coumarin. The post-operative course was delayed by non-
cardiac complications, including an infection of the femoral punc-
ture site with methicillin-resistant Staphylococcus aureus. Three
weeks after implantation, the patient was discharged to a cardiac
rehabilitation programme. During follow-up visits, she reported
improved physical capacity from NYHA functional class IV to III.
Figure 3 Echocardiographic evaluation of prosthetic valve function systolic closure (A and B) and diastolic opening (C and D) of the pericardial
valve is visualized by transoesophageal echocardiography after the implantation procedure. Short- and long-axis views of the device after
deployment. Doppler interrogation conﬁrmed valvular competence and a continuously antegrade blood ﬂow in the inferior vena cava and
the hepatic veins without ﬂow reversal.
A. Lauten et al. 1210Peripheral oedema did not recur and ascites resolved partially,
however remained detectable secondary to hepatic cirrhosis.
Discussion
This ﬁrst report of transcatheter treatment of severe TR in a
human patient demonstrates the feasibility of self-expanding valve
implantation into the IVC with leading to a prompt haemodynamic
and short-term clinical improvement. After deployment, excellent
valve function was documented with an immediate abolition of IVC
regurgitation (Figures 3 and 4). Paravalvular leakage and systolic
ﬂow reversal in the IVC and the hepatic veins were ruled out by
angiography at the time of implantation and by Doppler interrog-
ation during follow-up. Valve function remained unchanged
during sequential assessment. During early follow-up, the patient
experienced a reduction in clinical symptoms associated with
venous congestion and an improvement of physical capacity from
NYHA IV to NYHA III functional class.
In contrast to our previous experience in animals reporting
double-valve implantation into the IVC and superior vena cava
(SVC), in this ﬁrst human case, we implanted a single valve into
the IVC only.
11 This rather simple procedure was performed
because the patient primarily suffered from symptoms associated
with IVC congestion, as well as for several technical reasons.
From pre-clinical experience, we were aware of the fact that in
severe TR, anchoring a self-expanding valve at the upper cavoa-
trial junction can be associated with complications due to the dis-
tention of the SVC. In our patient, imaging studies had revealed a
severe enlargement of the RA resulting in a ‘funnel-shape’ of the
SVC cavoatrial junction, a condition involving a high risk of valve
migration into the RA following deployment of the current
device. Moreover, the presence of a pacemaker lead would
Figure 4 After device implantation, (A) deployment of the self-expanding valve resulted in the immediate abolition of regurgitation into the
inferior vena cava. Simultaneous pressure measurement in the right atrium and the inferior vena cava conﬁrms a reduction in the v-wave. (B)A
computed tomographic angiogram 8 weeks after implantation with contrast injected in superior vena cava visualizes valve function without
backﬂow into the inferior vena cava. The level of the leaﬂets (asterisks) is aligned with the cavoatrial junction, thus protecting of the
hepatic vein from elevated right atrium pressure. (C) Three-dimensional reconstruction conﬁrms the forward-tilted position of the valve in
the inferior vena cava. (D) Transthoracic echo after 8 weeks visualizes right atrial and right ventricular enlargement; however, right heart mor-
phology and function remained unchanged compared with the (E) pre-operative state. RA, right atrium; RV, right ventricle; IVC, inferior vena
cava; LA, left atrium; PA, pulmonary artery. Previously implanted devices (pacer leads, prosthetic mitral valve) are marked with #.
Heterotopic transcatheter TV implantation 1211have potentially complicated sufﬁcient anchoring of the SVC
device.
In patients with severe TR and multiple co-morbidities, TV
surgery is frequently rejected because of a prohibitive operative
risk. Reoperations for recurrent TR are particularly high-risk pro-
cedures with an in-hospital mortality of up to 37%. In addition,
pharmacological therapy is often ineffective in achieving sustained
improvement of symptoms.
10 In our patient, surgical TV repair
or replacement was no option both for technical reasons and
due to signiﬁcant co-morbidities. In contrast, percutaneous valve
implantation into the IVC was easily performed in a straightfor-
ward approach without difﬁculties. Haemodynamic improvement
was achieved by a reduction in IVC regurgitation as well as the
improvement of symptoms of IVC congestion in this particular
case. Nevertheless, the long-term clinical beneﬁt in patients with
TR in end-stage heart disease has not yet been investigated, and
thus, there is a need for conﬁrmation by further clinical experience
and a longer follow-up period.
When considering this treatment concept for TR in human
patients, several technical as well as physiological limitations have
to be acknowledged. Severe TR is associated with structural
changes of the RA and the caval veins. In these patients, the ana-
tomic diameter of the IVC may show a substantial variation (reach-
ing a diameter of up to 45 mm in isolated cases), thus requiring a
speciﬁc, potentially individual solution for the device design and
implantation procedure. In contrast to other stent valves available
for transcatheter aortic valve implantation, the larger diameter of
the IVC valve poses additional difﬁculties for tissue valve engineer-
ing. Along with the diameter, the biological valve proﬁle has to be
increased to avoid leaﬂet prolapse (e.g. a 45 mm tissue valve would
require a height of .28 mm corresponding to a height-to-
diameter ratio of 62%).
Secondly, the haemodynamic proof of IVC regurgitation is
required prior to heterotopic valve implantation. In particular, in
chronic TR with RA and RV enlargement, the RA functions as a
reservoir by reducing the prominence of the ventricular wave and
limiting the backﬂow of blood to the IVC. As pulsatile blood ﬂow
and systolic ﬂow reversal in the IVC are prerequisites for proper
valve function, the IVC valve is likely to have a haemodynamic
effect only in patients with severe TR and preserved RV function.
12
The signiﬁcance of preserved RV function is already known to affect
outcome after TV surgery and, to a certain degree, should also be
takenintoaccountininterventionalTVreplacement.Theprocedure
results in ventricularization of the RA with persistence of RV and
atrial volume overload. Right ventricular preload may actually
increasewithasubsequentriseincardiacoutputasobservedinpre-
clinical studies. However, although not observed in this case, the
increase in RV preload may promote further morphological
changes of the RA and RV with potential deleterious effects on
cardiac function and rhythm during long-term follow-up. In patients
with severely reduced RV function or severely elevated pulmonary
artery pressure, an increase in preload after device implantation
may promote RV failure. Thus, these patients are rather unlikely to
proﬁt from the procedure.
Thirdly, IVC valve implantation only addresses the regurgitation
of blood into the IVC. After valve deployment, the hepatic veins
have to be protected from elevated atrial pressure, but must not
be obstructed by the device. In this context, our concept of design-
ing a valve protruding into the RA and anchored in the IVC with a
long stent has proven to be successful. As observed in pre-clinical
animal studies, the caval valves demonstrated a strong ﬁxation to
the venous wall after 4 weeks due to ﬁbrous covering, thus
making device migration beyond this time point highly unlikely. Fur-
thermore, valve implantation in the low-ﬂow and low-pressure
venous circulation requires lifelong oral anticoagulation to
prevent device thrombosis.
In summary, we herein present the ﬁrst human case of IVC valve
implantation in a non-surgical patient suffering from severe TR and
refractory symptoms of venous congestion resulting in haemo-
dynamic improvement and early symptomatic relief. This interven-
tional concept is targeted for a severely ill group of patients with
signiﬁcant TR not amenable to surgical valve repair or replacement
in end-stage heart disease. Further studies are required to evaluate
the clinical beneﬁt of the procedure during long-term follow-up.
Additional indications may arise depending on clinical experience
and long-term animal studies. Although the treatment offers a high
likelihood for clinical improvement in this severely ill subgroup of
patients, the costs involved for this type of procedure should be
taken into account and carefully weighed against the clinical beneﬁt.
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Prospectively ECG-triggered 256-slice computed tomography ﬁndings in a
patient with dextrocardia, stent-treated coarctation, and infracardial
right-sided pulmonary vein deviation
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A 13-year-old female patient with Turner syndrome and complex con-
genital heart disease including aortic coarctation presented to our hos-
pital. Stenting of the coarctation was successfully performed with an
open-cell-design non-covered stent (ev3 MaxLD). Due to the short
distance between the left subclavian artery origin and the coarctation,
partial overstenting of the subclavian artery was accepted. Post-
stenting angiography demonstrated good patency of the subclavian
artery, no dissections, and no residual pressure drop over the stent.
Because Turner syndrome patients have a higher risk for aortic aneur-
ysm, she underwent contrast-enhanced cardiac CT scan to check stent
patency and positioning 6 weeks after stenting. Scanning was per-
formed on a 256-slice scanner (Philips, the Netherlands) using pro-
spective ECG-triggering timed at diastole using 80 KV and 195 mAs.
Heart rate during scanning was 90 b.p.m. Radiation dose to the
patient was only 1.3 mSv. The CT scan conﬁrmed the adequate pos-
ition of the stent without aneurysm formation and good left subclavian
artery contrast ﬁlling distal to the stent (arrowhead Panel A, arrow
Panel C). Furthermore, CT demonstrated dextrocardia, bicuspid
aortic valve (Panel D), and abnormal pulmonary venous return of the right lung to the inferior caval vein (arrows Panels A and B)
with an enlarged right ventricular cavity (RV, Panel E). No right pulmonary artery hypoplasia or sequester was seen. The left pulmonary
veins drained regular into the left atrium (LA, Panel A). Current high-end CT scanners can provide ECG-triggered imaging of complex
congenital heart disease at a low radiation dose to the patient.
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2010. For permissions please email: journals.permissions@oup.com.
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